Biden administration to retire 'Operation Warp Speed' name
January 15, 2021 -- The incoming Biden administration said that it will no longer use the "Operation Warp Speed" term to describe the U.S. government's efforts to combat the COVID-19 pandemic.
LabCentral debuts platform to attract people to biotech
January 13, 2021 -- LabCentral has launched a platform that aims to broaden and diversify the biotech industry's base of talent.
Tessera closes $230M in series B round for gene writing tech
January 12, 2021 -- Tessera Therapeutics has raised over $230 million in series B financing to advance its gene writing technology, capable of writing therapeutic instructions into the genome to treat diseases at their source.
AbSci acquires Denovium for protein AI platform
January 12, 2021 -- AbSci, a synthetic biology company, has acquired Denovium, an artificial intelligence (AI) deep-learning company.
Thermo Fisher launches managed equipment plan
January 7, 2021 -- Thermo Fisher Scientific has launched a new subscription-based program called Managed Equipment Solutions that combines instrument and equipment sales with application and service support, software, and training.
MilliporeSigma acquires AmpTec
January 7, 2021 -- MilliporeSigma has purchased messenger RNA firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture messenger RNA for use in COVID-19 vaccines and treatments.
Vizgen debuts accelerator lab in the U.S.
January 6, 2021 -- Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.
Twist to offer RNA control for U.K. strain of SARS-CoV-2
December 23, 2020 -- Twist Bioscience plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the U.K. and South Africa.
Mettler-Toledo announces CEO transition
December 16, 2020 -- Mettler-Toledo International has announced that Patrick Kaltenbach will take over as CEO in the spring.
Locanabio nabs $100M in series B round for RNA-targeting gene therapies
December 14, 2020 -- Locanabio has raised $100 million in a series B funding round to further develop its novel RNA-targeting platform and to advance multiple programs to investigational new drug-enabling studies in 2021.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter